

## **Intersect ENT Announces Appointment of Cynthia L. Lucchese to Board of Directors**

Menlo Park, Calif. – July 11, 2014 – Intersect ENT, Inc., a commercial drug-device company committed to improving the quality of life for patients with ear, nose and throat conditions, today announced the appointment of Cynthia L. Lucchese to the company's board of directors. Ms. Lucchese will serve as chair of the audit committee and as a member of the nominating and governance committee.

Ms. Lucchese has extensive financial management experience. She most recently served as senior vice president and chief financial officer of Hillenbrand, Inc. (NYSE: HI), and as a member of the board of directors of Brightpoint, Inc. (NASDAQ: CELL), where she served as chair of the audit committee. Previously, Ms. Lucchese was senior vice president and chief financial officer for Thoratec Corporation (NASDAQ: THOR) and held a variety of finance roles, including vice president and treasurer and chief accounting officer, at Guidant Corporation, now a part of Boston Scientific Corporation. She also spent seven years with Eli Lilly and Company and several years with the audit division of Ernst & Young.

"I am thrilled to join the board and to assist the company in its mission of addressing the clear need for better solutions for ENT physicians and their patients," said Ms. Lucchese. "I am excited to be a part of the next chapter of the organization."

"Cindy has a wealth of accounting and public company experience combined with a strong background in the medical device industry," said Lisa Earnhardt, president and chief executive officer of Intersect ENT. "Cindy brings a seasoned, global perspective to the board as we seek to expand access to our technology in the United States and worldwide."

### **About Intersect ENT**

Intersect ENT, Inc. is a commercial drug-device company committed to improving the quality of life for patients with ear, nose and throat conditions. Intersect ENT's drug-eluting bioabsorbable implant technology enables targeted and sustained release of therapeutic agents. Intersect ENT's initial products, PROPEL and PROPEL mini, are the first and only drug-eluting implants approved for use in patients with chronic sinusitis. Use of the PROPEL implants is clinically proven to improve surgical outcomes by maintaining the open pathways created in surgery and reducing the need for oral steroids and additional surgical procedures. In addition, Intersect ENT is developing new, less invasive and more cost-effective drug-eluting bioabsorbable treatment options for the management of chronic sinusitis in the physician office setting to provide benefits for patients, physicians and payors.

###

Media Contact:	Nicole Osmer 650.454.0504 <a href="mailto:nicole@nicoleosmer.com">nicole@nicoleosmer.com</a>
Investor Contact:	Jeri Hilleman 650.641.2105 <a href="mailto:ir@intersectent.com">ir@intersectent.com</a>